Celltech reports CDP870 Phase II data

Celltech (LSE:CCH; CLL) and partner Pharmacia (PHA) said data from a 203-patient Phase II trial showed 60%, 40% and 29% of rheumatoid arthritis patients given 400 mg (the highest dose) of CDP870 had A...